Seeking Funding For Cancer Vaccine Clinical Trial And Fast Track Commercialization
The company secured ownership and rights to market the Cuban technology globally for US$32 million.
"We are looking for investors to come into the project," said Chairman Mukhriz Mahathir. He said that the funds raised will be used for Phase II and III clinical trials for its EGF cancer vaccine and hepatitis B therapeutic vaccine in Asian and European sites. The monies will also be used for listing the company in 2 years time.
The company has embarked on Phase II/III clinical trials on the breakthrough cancer vaccine products, the most developed of which is the Epidermal Growth Factor (EGF) cancer vaccine on terminally ill, late stage non-small cell lung cancer (NSCLC) patients.
The head of the project, Dr Gisela Gonzalez Marinello, notes that the EGF is not a prophylactic vaccine but fights the regeneration of carcinogenic cells. It is injected once a month as a complement to traditional treatments such as chemotherapy and radiotherapy.
The vaccine has proven effective in trials carried out in Cuba, Canada and the United Kingdom by extending the lives of terminally ill cancer patients by up to two years compared to 6 months using existing treatments according to Dr Gonzalez.
She said that Cuba has already started the EGF cancer vaccine Phase III clinical trials on the cancer vaccine on terminally ill, late stage non-small cell lung cancer (NSCLC) patients. We hope to register the product in Cuba for use on patients by mid 2008.
As of today, twelve hospitals in Malaysia have already started to recruit patients who have late stage cancer. Bioven aims to recruit up to 230 patients to conduct clinical trials. To reach these goals and to ensure approval in their new European territories, Bioven has identified trial sites in Europe, including London.
"The outcome of this clinical trial will have global implications by bringing new hope to cancer patients. The clinical trials in Malaysia and Europe are designed to demonstrate the cancer vaccine's ability to extend the lives of cancer patients and fast tracking global approval for the products," said Mukhriz.
The four products comprise of 3 Therapeutic Cancer Vaccines - EGF, TGF, HER-1 and the Nasal Spray Hepatitis B Therapeutic Vaccine.
http://www.bioven.com.my
Cautare de finantare pentru cancer Vaccin studiul clinic ºi rapide Comercializare - Seeking Funding For Cancer Vaccine Clinical Trial And Fast Track Commercialization - articole medicale engleza - startsanatate